The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in relapsed myeloma
Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses the Phase II/III SUCCESSOR-2 (NCT05552976) results evaluating mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in heavily pretreated relapsed or refractory multiple myeloma. He highlights a doubling of progression-free survival (PFS) compared with carfilzomib and dexamethasone, supporting the potential of this outpatient regimen in relapsed disease. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In the SUCCESSOR-2 study, patients were included that were relatively heavily pretreated. They had received a median of two prior lines of therapy and about a quarter of these patients had received four or more prior lines of therapy. Furthermore, all these patients were exposed and most of them refractory to both lenalidomide and anti-CD38. So in the context of this particular patient population, we saw a doubling of progression-free survival as compared to the control arm, carfilzomib and dexamethasone...
In the SUCCESSOR-2 study, patients were included that were relatively heavily pretreated. They had received a median of two prior lines of therapy and about a quarter of these patients had received four or more prior lines of therapy. Furthermore, all these patients were exposed and most of them refractory to both lenalidomide and anti-CD38. So in the context of this particular patient population, we saw a doubling of progression-free survival as compared to the control arm, carfilzomib and dexamethasone. I believe that these data are very encouraging. There are patients that could be treated with this regimen. This regimen can be given to outpatients. Lenalidomide is given orally. Carfilzomib is given intravenously every week. It could be given on an outpatient basis and even in small practice settings. So I believe that this is an important combination for the treatment of myeloma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
